Earnings summaries and quarterly performance for ORAMED PHARMACEUTICALS.
Executive leadership at ORAMED PHARMACEUTICALS.
Board of directors at ORAMED PHARMACEUTICALS.
Research analysts covering ORAMED PHARMACEUTICALS.
Recent press releases and 8-K filings for ORMP.
Oramed and Lifeward Announce Strategic Transaction
ORMP
M&A
New Projects/Investments
Debt Issuance
- Oramed Pharmaceuticals (ORMP) and Lifeward Ltd. (LFWD) have signed binding agreements for a strategic transaction, transferring Oramed's POD™ oral drug delivery technology to Lifeward. Oramed will obtain a 49.9% beneficial ownership interest in Lifeward, including warrants, and is expected to manage the upcoming clinical trial for the POD™ platform.
- Oramed will invest $9 million in an initial $10 million senior secured convertible note issued by Lifeward, with an additional milestone-based $9 million investment in a second $10 million convertible note. Oramed will also receive 4% on net sales of Lifeward's ReWalk franchise for up to 10 years.
- Lifeward's FDA-approved ReWalk® and AlterG® products generated $26 million in revenue over the last four quarters.
Jan 13, 2026, 12:58 PM
Oramed Pharmaceuticals Announces Scilex Payment and Dividend Approval
ORMP
Dividends
New Projects/Investments
- Oramed Pharmaceuticals Inc. has received an $18 million payment from Scilex Holdings Inc., which fully satisfies the obligations under their Option Agreement.
- This payment increases Oramed's current returns to $118 million on its original $99.5 million investment in Scilex, with additional returns anticipated from retained notes, warrants, and a nine-year royalty interest.
- The company's Board of Directors has approved a cash dividend payment of $0.25 per share, which is expected to result in an aggregate distribution of approximately $10.5 million.
- The dividend will have an ex-dividend date of January 16, 2026, and is scheduled for disbursement on January 26, 2026.
Jan 7, 2026, 1:56 PM
Oramed Pharmaceuticals Announces Payment from Scilex and Dividend Approval
ORMP
Dividends
New Projects/Investments
- Oramed Pharmaceuticals received an $18 million payment from Scilex Holdings Inc., bringing its current returns on its original $99.5 million Scilex investment to $118 million.
- The company retains a $27 million note and a $12 million convertible note with Scilex, convertible at $36 per share, along with warrants and a nine-year royalty interest in Scilex products.
- Oramed's Board of Directors approved a cash dividend of $0.25 per share, with an ex-dividend date of January 16, 2026, and disbursement scheduled for January 26, 2026.
- The dividend is expected to result in an aggregate distribution of approximately $10.5 million.
Jan 7, 2026, 1:55 PM
Oramed Pharmaceuticals Reports Strong Fiscal Third Quarter 2025 Financial Results
ORMP
Earnings
New Projects/Investments
- Oramed Pharmaceuticals Inc. reported a net income (pre-tax) of $65.0 million for the nine months ended September 30, 2025, a significant improvement from a net loss of $6.1 million in the same period last year.
- The company's total assets increased by 42%, growing from $155.3 million to $220.5 million year-over-year.
- This financial performance was primarily driven by the full repayment of $100 million from Scilex and substantial unrealized fair-value gains from equity holdings in Alpha Tau Medical Ltd. and other investments.
- Basic earnings per share for the nine-month period were $1.30, and diluted earnings per share were $1.26.
Nov 17, 2025, 2:05 PM
Oramed Pharmaceuticals Reports Nine-Month 2025 Financial Results
ORMP
Earnings
New Projects/Investments
- Oramed Pharmaceuticals reported a net income (pre-tax) of $65.0 million for the nine months ended September 30, 2025, a significant improvement from a net loss of $6.1 million in the same period last year. This performance was primarily driven by the full $100 million repayment from Scilex and substantial unrealized fair-value gains from equity holdings in Alpha Tau Medical Ltd. and other investments.
- The company's total assets increased 42% to $220.5 million year-over-year, with basic earnings per share of $1.30 and diluted earnings per share of $1.26 for the nine-month period.
- Research and development expenses decreased from $4.9 million to $4.4 million, while general and administrative expenses increased from $4.3 million to $5.0 million for the nine months ended September 30, 2025.
Nov 17, 2025, 1:56 PM
Oramed Pharmaceuticals Adopts Rights Plan and Declares Dividend Distribution
ORMP
Dividends
Takeover Bid
- Oramed Pharmaceuticals Inc. (ORMP) adopted a Rights Agreement on November 17, 2025, and declared a dividend of one common stock purchase right on each outstanding share of its common stock.
- The Rights Plan is designed to ensure fair and equal treatment for stockholders in the event of a hostile takeover and to enhance the Board's ability to negotiate with any prospective acquiror.
- Each Right initially entitles stockholders to purchase one share of Common Stock for $10.00 and becomes exercisable if a person or group acquires 15% or more of the outstanding Common Stock.
- The dividend distribution is payable on November 27, 2025, to stockholders of record as of the close of business on that date, and the Rights will expire three years after the date of adoption.
Nov 17, 2025, 1:50 PM
Oramed Pharmaceuticals Inc. Updates on Oral Insulin Program, Investment Portfolio, and Shareholder Returns
ORMP
New Projects/Investments
Share Buyback
Dividends
- Oramed Pharmaceuticals Inc. is independently advancing its oral insulin program with a new 60-patient U.S. trial, following the termination of its joint venture with Hefei Tianhui Biotech Co. Ltd..
- The company's diversified investment portfolio has yielded substantial returns, including a $27.1 million gain on its Alpha Tau Medical Ltd. investment and $95.5 million returned from a loan to Scilex Holdings.
- Total cash and assets increased to approximately $210 million as of September 30, 2025 (unaudited), from $155.7 million in January 2023, while also investing $17.8 million in R&D and share buybacks.
- Oramed repurchased 1,155,367 shares for $2,576,468.41 on October 20, 2025, and reaffirms plans for a one-time dividend to shareholders.
Oct 23, 2025, 11:39 PM
Ask Fintool AI Agent
Get instant answers from SEC filings, earnings calls & more